Journal of
Medical Laboratory and Diagnosis

  • Abbreviation: J. Med. Lab. Diagn.
  • Language: English
  • ISSN: 2141-2618
  • DOI: 10.5897/JMLD
  • Start Year: 2010
  • Published Articles: 55

Full Length Research Paper

What is the best approximation of reference normal for NT-proBNP? Clinical levels for enhanced assessment of NT-proBNP (CLEAN)

Larry H. Bernstein
  • Larry H. Bernstein
  • 1New York Methodist Hospital, Brooklyn, New York, USA.
  • Google Scholar
Michael Y. Zions
  • Michael Y. Zions
  • 1New York Methodist Hospital, Brooklyn, New York, USA. 4Touro College, Brooklyn, New York, USA.
  • Google Scholar
Mohammed E. Alam
  • Mohammed E. Alam
  • New York Methodist Hospital, Brooklyn, New York, USA. Medgar Evers College, Brooklyn, New York, USA.
  • Google Scholar
Salman A. Haq
  • Salman A. Haq
  • New York Methodist Hospital, Brooklyn, New York, USA
  • Google Scholar
John F. Heitner
  • John F. Heitner
  • New York Methodist Hospital, Brooklyn, New York, USA
  • Google Scholar
Stuart Zarich
  • Stuart Zarich
  • Bridgeport Hospital, Bridgeport, Connecticut, USA.
  • Google Scholar
Bette Seamonds
  • Bette Seamonds
  • Mercy Catholic Medical Center, Darby, Philadelphia, Pennsylvania, USA.
  • Google Scholar
Stanley Berger
  • Stanley Berger
  • Mercy Catholic Medical Center, Darby, Philadelphia, Pennsylvania, USA.
  • Google Scholar


  •  Accepted: 08 March 2011
  •  Published: 31 March 2011

Abstract

The natriuretic peptides, B-type natriuretic peptide (BNP) and NT-proBNP that have emerged as tools for diagnosing congestive heart failure (CHF) are affected by age and renal insufficiency (RI). NT-proBNP is used in rejecting CHF and as a marker of risk for patients with acute coronary syndromes. This observational study was undertaken to evaluate the reference value for interpreting NT-proBNP concentrations. The hypothesis is that increasing concentrations of NT-proBNP are associated with the effects of multiple co-morbidities, not merely CHF, resulting in altered volume status or myocardial filling pressures. NT-proBNP was measured in a population with normal trans-thoracic echocardiograms (TTE) and free of anemia or renal impairment. Study participants were seen in acute care for symptoms of shortness of breath suspicious for CHF requiring evaluation with cardiac NT-proBNP assay. The median NT-proBNP for patients under 50 years is 60.5 pg/ml with an upper limit of 462 pg/ml, and for patients over 50 years the median was 272.8 pg/ml with an upper limit of 998.2 pg/ml. We suggest that NT-proBNP levels can be more accurately interpreted only after removal of the major co-morbidities that affect an increase in this peptide in serum. The PRIDE study guidelines should be applied until presence or absence of comorbidities is diagnosed. With no comorbidities, the reference range for normal over 50 years of age remains steady at ~1000 pg/ml. The effect shown in previous papers likely is due to increasing concurrent comorbidity with age.

 

Key words: Congestive heart failure, natriuretic peptides, anemia, chronic renal insufficiency.